Announced Fri, 24 Jul · 13:45 IST
Dr Lal PathLabs Q1 profit up, INR 5 dividend, two acquisitions approved
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.7%1-day move
₹1690.10
prior close
₹1696.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+0.1+0.3+2.1+7.7—————————
Up moveDown movePending
AI summary
Dr Lal PathLabs Q1 FY27 consolidated revenue rose to INR 7,977 Mn (vs 6,698 Mn YoY), PAT at INR 1,705 Mn vs 1,340 Mn. Board declared interim dividend of INR 5 per share, record date July 30. Also approved 119,300 stock options under RSU Plan 2025. Two acquisitions cleared: 80 percent stake in Ghana-based Sunshine Healthcare for GHS 45.6 Mn (around INR 380 Mn), and 30 percent stake in Neuome Technologies for up to INR 35 Mn.
Likely market impact
Strong Q1 earnings and dividend payout lift shareholder returns; Africa and biobanking deals signal growth push beyond core India diagnostics.